Figure 3 from Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab)

Authors:
Open Access
Publisher website
Google Scholar
Abstract
Impact of treatment on circulating CD4+ T cells over time. Participants (arm A n = 10; arm B n = 12) were evaluated for changes in circulating T cells from baseline by repeated measures modeling of log10-transformed data: (A) absolute number of Tregs, (B) absolute number of CD4+ T cells, and (C) Tregs as a percentage of CD4+ T cells. Each participant is represented by a dashed line, and the solid lines represent the model estimated change from baseline with 95% CI for each arm.